Phase I/II Trial of CD4-IgG2 [PRO 542] in HIV-Infected Children.
Latest Information Update: 25 May 2012
At a glance
- Drugs PRO 542 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 May 2012 Planned number of patients changed from 24 to 12 and additional lead trial centre identified as reported by ClinicalTrials.gov.as reported by ClinicalTrials.gov.
- 10 May 2012 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 13 Oct 2005 New trial record.